Riskpilot← Back to searchSign inGet full accessMLMC Therapeutics ApS
APSActiveCVR 41277688Bryggergården 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 2020— employeeswww.mlmctherapeutics.com
Revenue 2024
DKK -27K
+4% vs 2023
EBITDA margin
100.0%
-4% vs 2023
Equity ratio
-213.0%
Financial strength
Net profit 2024
DKK -135K
-10% vs 2023
| Revenue | DKK -27K | +4% |
| EBITDA | DKK -27K | -4% |
| Net profit | DKK -135K | -10% |
| Total assets | DKK 159K | -27% |
| Equity | DKK -339K | -66% |
| Employees | — | — |
Legal name
MLMC Therapeutics ApS
CVR number
41277688
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3. april 2020
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning i og udvikling af teknologi til produktion af oral medicin, samt aktiviteter, som efter ledelsens skøn naturligt står i forbindelse hermed.
Address
Bryggergården 2
Phone
+4520666044
Email
ms@fomtechnologies.com
Website
www.mlmctherapeutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -11 | -20 | -30 | -26 | -27 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -11 | -20 | -30 | -26 | -27 |
| Depreciation & amort. | -7 | -29 | -48 | -68 | -74 |
| EBIT | -18 | -49 | -78 | -93 | -101 |
| Net financials | -0 | -5 | -12 | -30 | -33 |
| Profit before tax | -18 | -54 | -90 | -123 | -135 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -18 | -54 | -90 | -123 | -135 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 75 | 176 | 220 | 217 | 159 |
| Equity | 62 | 8 | -82 | -205 | -339 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 168 | 302 | 421 | 498 |
| Total debt | 13 | 168 | 302 | 421 | 498 |
EBITDA margin
-2663800.0%
This company
15.8%
Market median
-16859594% vs market
20202024
Equity ratio
-213.0%
This company
38.2%
Market median
-658% vs market
20202024
Return on equity
-13452500.0%
This company
18.4%
Market median
-73111513% vs market
20202024
Net profit margin
-13452500.0%
This company
8.1%
Market median
-166080347% vs market
20202024
Asset turnover
-0.17×
This company
1.12×
Market median
-115% vs market
20202024
Debt / equity
1.47×
This company
0.62×
Market median
-137% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-04-03 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MH Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FOM TECHNOLOGIES A/S | Company | 50.0% | 50.0% | 2020 |
CORIDATS CAPITAL ApS | Company | 10.0% | 10.0% | 2020 |
FOMT HOLDING ApS | Company | 10.0% | 10.0% | 2020 |
HDJ & LEJ Invest ApS | Company | 5.0% | 5.0% | 2020 |
| Individual | 5.0% | 5.0% | 2021 | |
Scantox Ballerup ApS | Company | 5.0% | 5.0% | 2020 |
| Individual | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CORIDATS CAPITAL ApS
MLMC Therapeutics ApS Board members of MLMC Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Henrik Stadi | Chief Executive Officer | 0 companies |
| Peter Gudmund Nielsen | Board of Directors | 0 companies |
| Martin Kiener | Chairman | 0 companies |
| Hanne Damgaard Jensen | Board of Directors | 0 companies |